Avid Bioservices has a performance score of 4 out of 100. The company's Beta, a measure of market volatility, is 2.8, indicating a relatively high risk compared to the market. This suggests that Avid Bioservices may outperform the market when it rises, but could underperform when the market declines. It's recommended to review Avid Bioservices' potential upside, as well as the relationship between its total risk alpha and kurtosis, to make an informed decision on whether its price patterns will revert.
Primary Takeaways
Despite a high coefficient of variation at
4K and a total risk alpha of -0.68, Avid Bioservices' stock may still be a promising investment opportunity. The company's shares have shown considerable resilience, ranging from a 52-week low of $4.07 to a high of $21.05, and with a last price of $6.5, there is potential for substantial growth, especially considering the company's net income of
$560K.
What is the right price you would pay to acquire a share of Avid Bioservices? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
What is happening with Avid Bioservices this year
Annual and quarterly reports issued by Avid Bioservices are formal
financial statements that are published yearly and quarterly and sent to Avid stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Avid Bioservices often view their annual report as an effective marketing tool to disseminate their perspective on company
future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Avid Bioservices Gross Profit
Avid Bioservices Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Avid Bioservices previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Avid Bioservices Gross Profit growth over the last 10 years. Please check Avid Bioservices'
gross profit and other
fundamental indicators for more details.
Breaking it down
Average experts consensus on the entity has changed. Currently, most analysts have less confidence in the stock as compared to a month ago. The current buy or sell recommendation of 5 analysts is Strong Buy.
Is Avid a risky opportunity?
Let's check the volatility. Avid is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Avid (USA Stocks:CDMO) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. obtaining a share of an Avid Bioservices stock makes you a part-owner of that company.
Avid Bioservices Current Consensus
Here is the recent trade recommendation based on an ongoing consensus estimate among financial analysis covering Avid Bioservices. The Avid consensus assessment is calculated by taking the average estimates from all of the analysts covering Avid Bioservices.
| Strong Buy | 3 | 60.0 |
| Buy | 1 | 20.0 |
| Hold | 1 | 20.0 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
"As the saying goes, 'buy low, sell high', Avid Bioservices stock could be a potential investment goldmine waiting to be unearthed. Despite a 52-week high of $21.05, the stock is currently hovering around the 50-day moving average of $7.01, presenting a potential upside of nearly 10%. However, the stock carries a Beta of 1.65, indicating it's more volatile than the market, which could be a concern for risk-averse investors. On the bright side, the company's current ratio stands at a healthy 1.93X, suggesting it has sufficient resources to meet its short-term obligations. Yet, with a probability of bankruptcy at 47%, potential investors must weigh the risks against the potential rewards."
Avid showing symptom of lower volatility
Avid Bioservices, a key player in the biotech sector, shows signs of decreasing volatility, making it potentially attractive to risk-averse investors. The firm's semi-variance, a gauge of price shifts, has fallen to 43.56, suggesting a possible reduction in stock volatility. This could position it as a more stable investment. It's crucial for investors to closely watch Avid Bioservices as this lower volatility may offer a prime investment opportunity. The company exhibits above-average volatility over the chosen timeframe. Understanding these volatility trends can aid investors in market timing. Utilizing volatility indicators properly allows traders to assess Avid Bioservices' stock risk in relation to market volatility, in both bullish and bearish trends.
The heightened volatility in bear markets can impact
Avid Bioservices' stock price and cause investor stress, often leading to portfolio rebalancing with different financial instruments. Despite a modest market decline, Avid Bioservices has made a strong advance today, outperforming expectations. The analyst overall consensus remains a
Strong Buy, with three strong buys, one buy, and only one hold. This is bolstered by a robust analyst target price estimated value of
$19.25, indicating substantial potential for growth. With the fiscal year end approaching in April, investors may find this an opportune moment to consider Avid Bioservices. While there's a possible downside price of $1.04, the possible upside price of $13.69 and the highest estimated target price of $21.37 are encouraging. In conclusion, Avid Bioservices presents a promising investment opportunity given its strong performance and favorable analyst consensus. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Avid Bioservices. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
